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A B S T R A C T
Background: Isoniazid (INH) is the mainstay antimicrobial in the treatment of tuberculosis (TB). It is acetlylated
in the liver to acetyl-INH. However, there is variation in rate of acetylation of INH among TB patients (i.e. fast,
intermediate or slow acetylators) which impacts on the treatment outcomes.
Aim: The isoniazid acetylation phenotypes in the expatriate Sudanese population were determined to provide
future guidance since TB is prevalent in Sudan.
Methods: A community-based trial among Sudanese expatriates in Saudi Arabia was undertaken to identify INH-
acetylation phenotypes. After overnight fasting, a single dose of 200mg of INH was given to the volunteers.
Three hours later, 5 ml of blood were drawn from each volunteer and prepared for High-Performance Liquid
Chromatography (HPLC) analysis. The main outcomes were INH and Acetyl-INH concentrations in plasma and
the subsequent Acetyl-INH/INH metabolic ratio (MR).
Results: The ﬁndings suggest that slow acetylation is highly prevalent among the study participants (n=43;
84.31%). Moreover, there was no statistically signiﬁcant correlation between age and the MR (r=−0.18,
P=0.20). Further, there was no signiﬁcant association between gender and the MR (P=0.124). Similarly, no
signiﬁcant association was found between smoking habits and MR (P=0.24).
Conclusion: Isoniazid phenotyping suggests predominantly slow acetylation among the Sudanese in this sample.
The study found no statistically signiﬁcant associations between the MR and age or gender or smoking.
1. Introduction
Appropriate diagnosis and management of tuberculosis (TB) is a
public health priority across countries [1,2], with TB still the second
leading cause of death from infectious diseases world-wide including
patients with concomitant HIV and TB [3–5]. The prevalence of TB in
Sudan is a concern [6], with growing numbers of patients during the
past ﬁve decades [7], although incidence rates are now decreasing [8].
This though may reﬂect under-reporting in conﬂict zones [9]. Overall,
Sudan is considered a country with a high prevalence of TB, with 6587
cases reported in 2012 [7].
TB is also a concern in Saudi Arabia, although incidence rates have
decreased in recent years through a number of government initiatives,
resulting in overall moderate prevalence rates [10–12]. Prevalence
rates for TB do vary throughout Saudi Arabia and are generally higher
among non-Saudis especially those coming from high prevalence
countries which includes Sudan [10]. There is a relatively higher rate of
multi-drug-resistant tuberculosis (MDR-TB) in Saudi Arabia compared
with Western countries [11], which must be carefully managed with
isoniazid a critical medicine although diﬀerent strategies have been
developed to manage MDR-TB [13–15].
The WHO recommends the 2HRZE/4RH regimen for new cases
(pulmonary and extrapulmonary TB), which includes two months in-
tensive treatment with four oral medicines, isoniazid (H), rifampicin
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(R), pyrazinamide (Z) and ethambutol (E), plus 4 months continuation
phase with rifampicin and isoniazid. Isoniazid (H) and rifampicin are
highly potent medicines to treat TB and they remain the cornerstone in
the management of TB world-wide [16]. They are predominantly
available together with other anti-TB medicines in ﬁxed-dose combi-
nations (FDC) [17,18]. Isoniazid can also be given as monotherapy for
prophylaxis purposes [19], and is a low-molecular-weight medicine
with a hydrophilic feature that can rapidly penetrate the gastro-
intestinal (GI) tract to reach the bloodstream [20].
The eﬀectiveness of anti-TB medicines are predominantly inﬂu-
enced by two pharmacokinetic parameters, namely the area under the
curve (AUC) and the maximum concentration (Cmax) in the blood.
Increased AUC value is proportionally correlated with the eﬃcacy of TB
drugs whereas low Cmax can precipitate antimicrobial resistance [21].
The pharmacokinetic characteristics of isoniazid are further inﬂuenced
by diﬀerent patient-related factors including age, genetic status, co-
morbidities, and concomitant administered other medicines or food
[22–24]. Isoniazid is converted to acetyl-isoniazid (Ac-INH) in the liver.
In turn, Ac-INH is cleaved into iso-nicotinic acid and mono-acetyl hy-
drazine (MAH). The latter is further acetalized to form di-phenyl hy-
drazine [25]. Genetic polymorphisms currently show diﬀerent fre-
quencies with various ethnic backgrounds [20,26]. Many studies have
indicated that the rate with which isoniazid is metabolized is controlled
by two alleles as a single autosomal gene locus. Homozygous for a re-
cessive allele determines slow acetylators whereas the homozygous or
heterozygous dominant gene controls fast acetylators [27]. The routine
incorporation of isoniazid into TB management protocols [14,18], and
the inﬂuence of genetic variability in its metabolism, led to considering
acetylation polymorphism [26]. Isoniazid acetylation status subse-
quently categorizes populations into slow, intermediate, or rapid acet-
ylators [28], with the distribution of acetylation status (slow versus
rapid acetylators) in the population being widely inﬂuenced by ethnic
background as well as environmental factors [20,26].
Isoniazid undergoes hepatic acetylation via hepatic N-acetyl-
transferase 2 (NAT2) to be converted to a toxic substance which ad-
versely impacts on the liver. Diversity in NAT2 plays a crucial part in
liver impairment [29], and consequently must be carefully managed.
Fast acetylators aﬀect the bioavailability of isoniazid and subsequently
confer drug resistance. Slow acetylators accumulate it beyond the
therapeutic level which in turn harms some organs including the liver.
Slow acetylation in particular has been found to be signiﬁcantly asso-
ciated with the risk of developing liver injury [30]. In fact, the in-
cidence of INH induced hepatotoxicity is higher in slow acetylators
[31,32]. For example, a study showed that the risk of developing INH
hepatotoxicity was 22% for slow acetylators compared to 2.9% in fast
acetylators [33]. This could be attributed to the higher accumulation of
INH and acetylhydrazide (Ac-Hz) metabolite in slow acetylators
[31,34]. In addition, fast acetylators are at a risk of liver toxicity [35].
This is a concern as most of the ﬁrst-line anti-TB medicines including
pyrazinamide and rifampicin also have harmful eﬀects on the liver.
However to date, there appear to be few published articles con-
cerning acetylation phenotyping among the Arab population [36]. We
are aware that the rate of slow acetylators has been shown to be 72.3%
among Saudi population using caﬀeine as a test substance [37] and the
frequency of slow acetylators among Jordanians has been found to be
67.5% using dapsone as a test substance [38]. In contrast, a study in-
volving 50 Egyptians using isoniazid as a test drug found the rate of
acetylation at 82% [39], with a study conducted among 40 healthy
Libyan male volunteers using sulphadimidine as a test substance
showed the rate of slow acetylators was 65% [40]. In addition, among
Moroccan TB patients where INH was employed as a test substance, the
rate of slow acetylators was 61.8% [41].
Currently, it appears there is no information concerning acetylation
phenotyping status using isoniazid as a test substance among the
Sudanese population in the published literature. This is important given
the high prevalence of TB in Sudan especially when combined with HIV
[7,8], the moderate prevalence of TB in Saudi Arabia which, as men-
tioned, is higher among some immigrant groups including those from
Sudan [10], the relatively high rate of MDR-TB in Saudi Arabia [11],
and the fact that the Sudanese population currently makes up 4% of the
expatriate population in Saudi Arabia [42]. In addition, Anggraini et al.
in Indonesia investigated the inﬂuence of acetylation status on the
treatment outcome and serum concentration of isoniazid. Despite the
lack of statistical signiﬁcance perhaps due to low patient numbers
(n=31), the risk of conversion failure was approximately two fold
greater among fast acetylators versus slow acetylators [43]. In view of
this, it appears worthwhile to consider acetylation phenotyping of pa-
tients for individualization of isoniazid dosage regimens among the
Sudanese population in Saudi Arabia.
Consequently, the purpose of the study was to describe the acet-
ylation status among the Sudanese in Saudi Arabia using isoniazid as a
test substance. In addition, the study aimed to examine whether there is
association between acetylation status and age, gender and the smoking
habits of participants. Understanding the acetylation phenotype of
isoniazid and possible factors serves as a robust base for further studies
to investigate factors correlated with the bioavailability that leads to
resistance and precipitating the harmful eﬀects of INH in a population
with a high prevalence rate of TB. These ﬁndings can serve as a basis for
further studies in Saudi Arabia as well as Sudan.
2. Method
2.1. Study setting
The study setting was community households located in Rafha in
the northern borders of Saudi Arabia. Rafha is the second most popu-
lated city in the region where the population is entirely urban. The
target population was healthy Sudanese residents who were living in
Rafha during the study period. The total number of Sudanese residents
in Rafha is estimated to be approximately 250 residents and whilst the
entire population (i.e. 250) was targeted, ﬁfty-one residents from both
sexes subsequently volunteered to participate in the study. The study
did not include TB patients as the TB patients in Rafha Central Hospital
(RCH) were non-Sudanese during the study period.
2.2. Study design and data collection
A prospective open-label study was conducted among Sudanese
volunteers residing in Rafha to principally measure phenotypes of iso-
niazid acetylation among this population. The selection criteria in-
cluded volunteer blood donors with no history of any drug therapy
within six months of commencement of the study. Patients with minor
ailments but not on therapy and having no clinical or laboratory evi-
dence of hepatobiliary, digestive, or renal disease were also included in
the study.
2.2.1. Sample collection and preparation
The study took place between February to August 2017. After
overnight fasting (from 12 midnight till 9 a.m.), each study subject
received a single oral dose of 200mg of isoniazid. Three hours later, a
venous blood (5ml) sample was drawn by a phlebotomist into an
Ethylene Diamine Tetraacetic Acid (EDTA) tube and promptly cen-
trifuged. The plasma was separated and frozen at −20-degree Celsius
for analysis. Collected samples were processed and analyzed in the re-
search lab in the Faculty of Pharmacy, Northern Border University
(NBU), Saudi Arabia. A single plasma sample taken 3 hrs post-INH oral
dose of 200mg is widely used in literature [36,44,45] to assess the
extent of isoniazid acetylation. As a result of the current eﬃcient essays
methods a 200mg is now considered suitable. Higher doses are no
longer considered necessary, avoiding nausea and other adverse eﬀects
associated with INH [45].
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2.2.2. Plasma concentration assays
The analysis for plasma concentrations for isoniazid and acetly-INH
was performed using Reverse Phase-High Performance Liquid
Chromatography (RP-HPLC), Waters® 2545 Quaternary Gradient
Module pump and equipped with Waters® 2998 diode array detector.
This entire analysis system was controlled using Empower 3 Software.
The column used in the system was water guard with asymmetry C18 of
5 μm, 4.6×150mm dimensions in an assembly of the Waters system
(Waters Assoc., Milford, MA, USA). Five μL volume of sample was in-
jected using Hamilton syringe. The chromatograms for INH and acetyl-
INH were obtained at 266 nm at room temperature with ﬂow rate of
1.4 ml/min at 900 psi pressure. No interferences with the peaks from
endogenous substances in the plasma were observed. Retention time
(RT) was 3.8min and 4.2 min for acetyl-INH and INH, respectively.
An isocratic mobile phase consisted of a mixture of 0.05M ammo-
nium acetate buﬀer (pH 6) and methanol (HPLC grade) (99:1, v/v),
respectively with an elution rate of 1.2 ml/min. Two concentrations of
ammonium acetate in water were administered as buﬀer solutions, 0.05
and 0.5M adjusted by glacial acetic acid and sodium hydroxide to pH 6
and 8.2, respectively.
Acetyl-INH was synthesized in the lab by reacting isoniazid with
acetic anhydride [46]. Various physical and chemical analytical
methods including nuclear magnetic resonance (NMR), Fourier-trans-
form infrared spectroscopy (FTIR), and the melting point characterized
its structure and purity [36].
2.2.3. Calibration curves of INH and Ac-INH
Five calibration standards of isoniazid and acetyl isoniazid (Ac-INH)
were prepared. Stock solutions of 1 g/L of pure INH and acetyl-INH
were prepared using HPLC grade methanol. The working solution
comprised 100 µg/ml INH and 200 µg /ml Ac-INH. Serial dilution with
the geometry of 2 was adopted to yield 0.5-1-2-4 and 8 µg/ml INH and
1-2-4-8 and 16 µg/ml Ac-INH.
2.2.4. Preparation of plasma samples for HPLC
To 300 µl of plasma, 250 µl of 10% (w/v) trichloroacetic acid as a
deproteinizing agent was added. The mixture was vigorously vortex-
mixed at a rate of 10,000 rpm for 10min. The trichloroacetic acid
portion (supernatant) was taken and diluted at a ratio of 1:1 with
ammonium acetate buﬀer (0.5 M, pH 8.20) to neutralize the excess acid
[44].
Ultimately, the plasma samples were injected and analyzed by re-
verse-phase high-performance liquid chromatography (RP-HPLC) and
the respective chromatogram peak areas of INH and Ac-INH were ﬁ-
nally measured digitally by the detector in the apparatus. The relevant
concentrations of both compounds were then calculated accordingly.
Plasma INH and acetyl-INH were determined by reverse-phase high-
performance liquid chromatography (RP-HPLC). On injecting the
working concentrations of both isoniazid and acetyl isoniazid (Acetyl-
INH) into the HPLC, peak areas were obtained which are documented in
Table 1. Pearson correlation coeﬃcients were found signiﬁcant
(P < 0.01) with almost perfect correlation for both isoniazid and its
metabolite, Acetyl-INH.
The acetylator phenotype was described by the histogram
distribution of the computed metabolic ratio (MR) of the levels of
acetyl-INH to isoniazid in plasma. The subjects were subsequently
classiﬁed based on the resultant histogram distribution. For every
participant, the plasma concentrations of isoniazid and Acetyl-INH
were calculated using the regression equations of both compounds.
These equations were derived from the regression line of the calibration
curves using the diﬀerent concentrations prepared for this purpose.
The regression line equations that correlate the ﬁnal concentration
with the peak areas were computed for both isoniazid and Acetyl-INH.
By least-squares method, a regression equation can be worked out
(Figs. 1 and 2). The closer the correlation coeﬃcient (Pearson) to unity,
the more signiﬁcant is the relation between the chromatogram peak
area and the concentration. Consequently, the obtained linear equation
can be used in any setting to determine unknown concentrations of INH
and Ac-INH.
2.3. Statistical analysis
Data were entered and organized using MS-excel. Moreover, the
data were then exported to IBM-SPSS version 24. The Pearson corre-
lation test was used to examine the correlation between age and MR,
whereas un-paired t-test was used to explore the association between
gender, smoking status and MR.
2.4. Ethical approval
The study received ethical approval from the Committee of
Bioethics at Northern Border University, Saudi Arabia with decision
number (4/38/H) and dated 5/01/2017. The purpose of the study was
clearly explained to the participants and written consents were then
taken.
Table 1
Peak areas values for the calibration curves of the working concentrations of
isoniazid and Acetyl-INH.
INH conc. (µg/ml) Peak areas Acetyl-INH conc. (µg/ml) Peak areas
0.50 6724 1 6655
1.00 14,884 2 13,414
2.00 32,300 4 31,112
4.00 70,532 8 55,214
8.00 168,903 16 91,248
NB: INH = isoniazid and Acetyl-INH = Acetyl isoniazid.
Fig. 1. Calibration curve of isoniazid solution.
Fig. 2. Calibration curve of Acetyl INH solution.
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3. Results
3.1. Characteristics of study participants
Of the 51 healthy volunteers who participated in the study, 29
(56.9%) were male. The mean age± SD of the participants was
34.3 ± 11.7 (range: 15–57) years. The mean age of males and
females± SD is comparable at 35 ± 11 years and 33 ± 13 years,
respectively. The number of smokers to non-smokers in the study group
was 43 (84.3%) and 8 (15.7%), respectively.
3.2. Main ﬁndings
The plasma concentrations of isoniazid and Acetyl-INH at 3 h post
200mg of isoniazid are shown in Table 2.
The overall metabolic ratio (MR) ± SEM of the volunteers was
4.02 ± 0.43 (Table 3)
The unpaired t-test showed no signiﬁcant association between
gender and the metabolic ratio (P=0.124) (Table 3). Similarly, no
signiﬁcant association was found between smoking habits (i.e. smokers
versus non-smokers) and MR (P=0.24).
The histogram (Fig. 3) showed bimodal distribution with an ap-
parent antimode of MR of 6 separating slow and fast metabolizer
groups. These ﬁndings show that slow acetylation is highly prevalent
among the study participants (n=43; 84.31%). Moreover, there was
no statistically signiﬁcant correlation between age and the Acetyl-INH/
INH ratio (r = −0.18, P=0.20) as shown in Fig. 4.
4. Discussion
We described the distribution of isoniazid acetylation phenotypes
based on the distribution of metabolic ratio (MR), Acetyl-INH/ iso-
niazid (Fig. 3). As mentioned, determination of acetylation by this
method is considered a reliable and useful method and widely used in
literature [36,41,44,45,47]. The results showed that the Sudanese vo-
lunteers in our sample were typically slow acetylators irrespective of
their age. The study also showed that no signiﬁcant association found
between gender and MR, which is similar to the ﬁndings of Rasmussen
and Brøsen in which gender did not impact on acetylation phenotypes
status [48]. However, this is diﬀerent to the ﬁndings of Asprodini et al.
who found a signiﬁcant association with gender [49]. We are not sure
of the reasons behind the diﬀerent results, and will be looking at this
Table 2
Plasma concentration of isoniazid & Acetyl-INH at 3 h post 200mg single dose
of Isoniazid.
Subject Peak area
(Ac-INH)
Ac-INH
Conc. (µg/
ml)
Peak area
(INH)
INH.
Conc.
(µg/ml)
Metabolic ratio –MR
(Ac-INH Conc./ INH.
Conc.)
1 17,260 2.23 3991 0.58 3.84
2 17,425 2.26 6242 0.68 3.32
3 15,986 2.00 3976 0.58 3.44
4 29,622 4.43 5589 0.65 6.81
5 15,067 1.84 12,449 0.97 1.90
6 24,589 3.54 7261 0.73 4.85
7 24,189 3.46 7581 0.74 4.68
8 15,289 1.88 4583 0.61 3.08
9 20,850 2.87 1892 0.48 5.98
10 12,532 1.38 4733 0.61 2.26
11 10,849 1.08 2134 0.49 2.20
12 16,195 2.04 3943 0.58 3.52
13 16,917 2.17 3649 0.56 3.88
14 17,015 2.18 4830 0.62 3.52
15 9596 0.86 28,172 1.69 0.51
16 14,689 1.77 5252 0.64 2.77
17 15,334 1.88 4830 0.62 3.03
18 14,145 1.67 9105 0.81 2.06
19 13,919 1.63 7556 0.74 2.20
20 18,035 2.37 1245 0.45 5.27
21 19,494 2.63 8001 0.76 3.46
22 7459 0.48 9654 0.84 0.57
23 25,434 3.69 5690 0.66 5.59
24 22,628 3.19 7649 0.75 4.25
25 16,252 2.05 2817 0.52 3.94
26 9260 0.80 2959 0.53 1.51
27 29,158 4.35 1778 0.48 9.06
28 42,082 6.66 7650 0.75 8.88
29 15,125 1.85 232 0.41 4.51
30 13,472 1.55 4741 0.61 2.54
31 11,674 1.23 10,253 0.87 1.41
32 31,223 4.72 1432 0.46 10.26
33 51,916 8.41 2497 0.51 16.49
34 22,292 3.13 8800 0.80 3.91
35 12,659 1.46 13,032 1.00 1.46
36 39,755 6.24 2570 0.51 12.24
37 12,078 1.30 9736 0.84 1.55
38 12,323 1.35 15,288 1.10 1.23
39 24,234 3.47 15,829 1.12 3.10
40 16,844 2.15 15,419 1.11 1.94
41 11,620 1.22 11,841 0.94 1.30
42 10,890 1.09 8104 0.77 1.41
43 18,320 2.42 11,432 0.92 2.63
44 11,233 1.15 12,969 0.99 1.16
45 31,625 4.79 5672 0.66 7.26
46 20,763 2.85 18,626 1.25 2.28
47 23,166 3.28 13,732 1.03 3.18
48 25,662 3.73 11,602 0.93 4.01
49 38,060 5.94 6242 0.68 8.74
50 15,773 1.96 4724 0.61 3.21
51 22,348 3.14 17,471 1.2 2.62
NB: INH = isoniazid and Acetyl-INH = Acetyl isoniazid.
Table 3
Metabolic ratios (MR) in diﬀerent subpopulation of 51 volunteers following
isoniazid intake.
Mean (μg/ml) S.E.M (μg/ml) N
Overall MR 4.02 0.43 51
Gender
Male 3.37 0.32 29
Female 4.87 0.89 22
Smoking habits
Smokers 2.82 0.70 8
Non-smokers 4.24 0.49 43
SEM: Standard Error of the Mean.
Fig. 3. Frequency distribution of plasma Acetyl-INH/INH ratios among ex-
patriates Sudanese in Saudi Arabia.
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further in future research.
It has also been shown that smoking is an enzyme inducer in dif-
ferent populations [50,51]. However, we did not ﬁnd any correlation
between smoking and MR, which is similar to the study of Asprodini
et al. who also found no association between MR and smoking [49].
Again, we are not sure of the reasons behind these diﬀerent ﬁndings,
and will be investigating this further.
Similar studies carried out among Africans concluded that both slow
and fast acetylators were prevalent among this population. Almost half
of the recruited Senegalese patients (55.7%) were found to be slow
acetylators in the study by Toure et al. [52], with comparable ﬁndings
also reported by Touré A et al. in a study involving subjects from West
Africa [53]. The rate of slow acetylators was reported to be 39% among
children in South Africa [54]. These studies indicate the prevalence of
slow acetylation among populations in Africa; however, the rates do
vary depending on the population studied.
These ﬁndings contrast with other populations where the pre-
valence of slow acetylation can be low, e.g. as low as 14.6% and 13.1%
among Indians and Japanese respectively and lower still (5%) among
Alaskan Eskimos. In the French and German population, the prevalence
of slow acetylation was reported to be 50% [44]. Out of 50 patients
recruited in a Libyan study, 24 (48%) exhibited slow acetylation [44].
These ﬁndings supported the fact that the rate of acetylation varies
from race to race; consequently, this needs to be taken into con-
sideration in clinical practice.
Chamorro and colleagues investigated factors associated with the
occurrence of anti-TB drug-induced hepatotoxicity (ATDH). Being slow
acetylators negatively impacted on liver toxicity (OR, 2.615; 95%CI
1.264–5.411), another reason for determining the extent of slow acet-
ylation among populations [55]. In addition, slow acetylators geno-
types among Indonesian Malay ethnic group were found to increase the
risk of cancer and liver injury [56], with, as mentioned, slow acetyla-
tion known to increase the risk of prostate cancer in Slovak populations
[57].
In terms of practical implications, as the majority of participants are
slow acetylators, the Sudanese may be at a higher risk of adverse eﬀects
associated with slow acetylation particularly liver injury. This indicates
the need for more care in terms of patient counselling, close monitoring
of adverse eﬀects and follow-up when these patients are prescribed
isoniazid. This is particularly important as most of the Sudanese TB
patients are working in remote areas in Saudi Arabia where contact
with clinicians is relatively limited. TB drug resistance may also de-
velop among Sudanese patients due to treatment default especially
during the continuation phase of treatment. Consequently, in-
dividualization of therapy and regular follow up of TB patients are
highly recommended in this population. In terms of therapeutic drug
monitoring (TDM), whilst acetylation status for isoniazid is of no
prognostic signiﬁcance in daily dosing regimen, it may be of sig-
niﬁcance in twice weekly dosing [58,59]. However, the World Health
Organization (WHO) current recommended regimen for TB is the daily
regimen. In addition, given current limited resources in Sudan, we
believe clinical monitoring of patients including incorporation of some
investigations such as liver function tests (ALT and AST) is re-
commended as a more practical approach compared to TDM approach,
which is hardly ever worthwhile for isoniazid [59]. These ﬁndings are
also important as certain diseases including prostate cancer appear
correlated with slow acetylators. The rate of prostrate cancer was ap-
proximately three times higher compared with fast acetylators pheno-
type (OR, 2.91; 95% CI 1.43 – 5.94) in a Slovak population [57].
Consequently, it would appear worthwhile monitoring the risk factors
associated with cancer.
Overall, we believe the study results could be of value for key sta-
keholders in both Sudan and Saudi Arabia as half a million Sudanese
residents are living in Saudi Arabia [42]. Moreover, whilst the overall
rate of MDR-TB among TB patients were 4.4% in a recent study by Al
Ammari et al., 63.4% of the cases were reported among the non-Saudi
population [11].
We are aware that there are a number of limitations with our study.
These include the fact that there was only a small number of partici-
pants and these were volunteers. However, the sample size is compar-
able to other similar studies in literature. In addition, in terms of
overnight fasting, the patients were instructed and well-informed not to
eat the night prior to the testing. However, it cannot be conﬁrmed that
all patients strictly adhered to the overnight fast which could have re-
sulted in delayed and decreased absorption, notably aﬀecting a single
time point plasma assessment. We also acknowledge that the volunteers
did not have TB at the time. Consequently, a larger-scale study would
be helpful to consider other pharmacokinetic parameters including
Cmax, and tmax, as well as look more closely at the extent of slow
acetylators among the Sudanese population including those with TB
Fig. 4. Relationship between plasma Acetyl-INH/INH ratio and age of expatriates Sudanese in Saudi Arabia (n=51, r = −0.18, P=0.20).
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and the implications. In addition, this study suggests that further ex-
ploration of NAT2 testing appears warranted in the Sudanese popula-
tion
5. Conclusion
In summary, in this study, the vast majority of the Sudanese vo-
lunteers were slow acetylators. Moreover, acetylation of isoniazid was
not associated with gender or smoking. Besides, no correlation was
detected between age and MR. This needs to be taken in consideration
in clinical practice when treating Sudanese patients with TB in Saudi
Arabia, particularly clinical monitoring of adverse eﬀects associated
with isoniazid. In addition, this study suggests that further exploration
of NAT2 testing appears warranted in the Sudanese population.
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